Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women.

Next Previous
Search
Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms BREEZE-2
  • Sponsors Assertio Therapeutics; Depomed

    • Most Recent Events

    • 12 Oct 2013 Pooled analysis of the BREEZE-1, -2 and -3 trials presented at the 24th Annual Meeting of the North American Menopause Society.
    • 31 Jul 2012 Additional results from the BREEZE programme will be reported at the 2012 North American Menopause Society Annual Meeting, according to a Depomed media release.
    • 24 Sep 2011 Results presented at the 22nd Annual Meeting of the North American Menopause Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top